Key Points
- David Malcom Rodman sold 416 shares on Jan. 20 at $32.10 for $13,353.60 and completed several larger January dispositions (notably 192,715 shares on Jan. 5 for ~$6.75M and 70,037 shares on Jan. 2 for ~$2.51M), leaving him with 50,437 shares (a 0.82% decline, ≈$1.62M).
- MLYS opened at $31.93, trades below its 50-day SMA of $37.86 but near its 200-day SMA of $31.54, has a 1-year range of $8.24–$47.65, and a market cap of about $2.53 billion.
- Analysts hold a consensus rating of Moderate Buy with a $47.43 price target (six Buys, one Hold, one Sell), and institutional investors own roughly 84.46% of the shares with several funds recently adding positions.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 416 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $32.10, for a total value of $13,353.60. Following the transaction, the insider directly owned 50,437 shares in the company, valued at approximately $1,619,027.70. This represents a 0.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
David Malcom Rodman also recently made the following trade(s):
- On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.61, for a total value of $370,677.87.
- On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.75, for a total value of $252,469.75.
- On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.32, for a total value of $205,167.36.
- On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $33.27, for a total value of $72,195.90.
- On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.87, for a total value of $2,512,227.19.
- On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.02, for a total transaction of $6,748,879.30.
Mineralys Therapeutics Price Performance
Shares of MLYS stock opened at $31.93 on Wednesday. The firm's 50-day simple moving average is $37.86 and its 200-day simple moving average is $31.54. Mineralys Therapeutics, Inc. has a 1-year low of $8.24 and a 1-year high of $47.65. The firm has a market cap of $2.53 billion, a P/E ratio of -10.82 and a beta of 0.49.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. Analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Mineralys Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Banque Pictet & Cie SA acquired a new position in Mineralys Therapeutics in the 4th quarter worth $272,000. Tema Etfs LLC purchased a new stake in shares of Mineralys Therapeutics during the fourth quarter worth about $235,000. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Mineralys Therapeutics by 31.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 69,362 shares of the company's stock worth $2,517,000 after acquiring an additional 16,514 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Mineralys Therapeutics by 130.7% in the fourth quarter. SG Americas Securities LLC now owns 230,795 shares of the company's stock valued at $8,376,000 after purchasing an additional 130,758 shares during the last quarter. Finally, Hudson Bay Capital Management LP purchased a new position in Mineralys Therapeutics in the third quarter valued at about $2,873,000. Hedge funds and other institutional investors own 84.46% of the company's stock.
Analyst Ratings Changes
Several brokerages have commented on MLYS. Weiss Ratings restated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Wednesday, October 8th. Wells Fargo & Company increased their target price on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 11th. Stifel Nicolaus raised their price target on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a report on Friday, December 19th. Finally, HC Wainwright boosted their price objective on shares of Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a "buy" rating in a research note on Wednesday, November 12th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $47.43.
View Our Latest Analysis on Mineralys Therapeutics
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
